DYNAMIC SPINAL VISUALIZATION

Similar documents
GENETIC TESTING FOR PREDICTING RISK OF NONFAMILIAL BREAST CANCER

ENDOBRONCHIAL ULTRASOUND FOR DIAGNOSIS AND STAGING OF LUNG CANCER

PANCREATIC ISLET TRANSPLANT

IMMUNE CELL FUNCTION ASSAY

GENETIC TESTING FOR TAMOXIFEN TREATMENT

HEMATOPOIETIC CELL TRANSPLANTATION FOR EPITHELIAL OVARIAN CARCINOMA

GENETIC TESTING FOR KRAS, NRAS AND BRAF VARIANT ANALYSIS IN METASTATIC COLORECTAL CANCER

MOLECULAR TESTING IN THE MANAGEMENT OF PULMONARY NODULES

PROTEOMIC TESTING FOR SYSTEMIC THERAPY IN NON-SMALL-CELL LUNG CANCER

RADIOFREQUENCY ABLATION OF PRIMARY OR METASTATIC LIVER TUMORS

DRUG TESTING IN PAIN MANAGEMENT AND SUBSTANCE USE DISORDER(S) TREATMENT

INTRAPERITONEAL CHEMOTHERAPY, CYTOREDUCTION

LARTRUVO (olaratumab)

MULTIMARKER SERUM TESTING RELATED TO OVARIAN CANCER

NOVEL BIOMARKERS IN RISK ASSESSMENT AND MANAGEMENT OF CARDIOVASCULAR DISEASE

BALLOON OSTIAL DILATION FOR TREATMENT OF CHRONIC SINUSITIS

INTERSPINOUS FIXATION (FUSION) DEVICES

FECAL ANALYSIS IN THE DIAGNOSIS OF INTESTINAL DYSBIOSIS

MEDICAL COVERAGE GUIDELINES ORIGINAL EFFECTIVE DATE: 10/04/17 SECTION: DRUGS LAST REVIEW DATE: LAST CRITERIA REVISION DATE: ARCHIVE DATE:

RADIOFREQUENCY ABLATION OF MISCELLANEOUS SOLID TUMORS EXCLUDING LIVER TUMORS

Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document.

GENETIC TESTING FOR MARFAN SYNDROME, THORACIC AORTIC ANEURYSMS AND DISSECTIONS AND RELATED DISORDERS

GENETIC TESTING FOR HEREDITARY HEARING LOSS

ALPHA1-PROTEINASE INHIBITORS

NEGATIVE PRESSURE WOUND THERAPY

CARDIOVASCULAR RISK PANELS

OPTICAL COHERENCE TOMOGRAPHY (OCT) OF THE MIDDLE EAR

ORAL IMPLANT PROCEDURES

NUTRIENT OR NUTRITIONAL PANEL TESTING

INTRAVITREAL IMPLANTS

CONTINUOUS OR INTERMITTENT GLUCOSE MONITORING IN INTERSTITIAL FLUID

DEEP BRAIN STIMULATION

INTRACAVITARY BALLOON BRACHYTHERAPY FOR MALIGNANT AND METASTATIC BRAIN TUMORS

PERCUTANEOUS BALLOON KYPHOPLASTY, RADIOFREQUENCY KYPHOPLASTY, AND MECHANICAL VERTEBRAL AUGMENTATION

GENE EXPRESSION PROFILING AND PROTEIN BIOMARKERS FOR PROSTATE CANCER MANAGEMENT

HEMATOPOIETIC CELL TRANSPLANTATION FOR PRIMARY AMYLOIDOSIS

ENTYVIO (vedolizumab)

DERMATOLOGIC APPLICATIONS OF PHOTODYNAMIC THERAPY

GENETIC TESTING FOR NEUROFIBROMATOSIS

GENETIC TESTING FOR FANCONI ANEMIA

PERJETA (pertuzumab) FOR TREATMENT OF MALIGNANCIES

GENETIC TESTING WITH MOLECULAR PANEL TESTING OF CANCERS TO IDENTIFY TARGETED THERAPIES

STELARA (ustekinumab)

TRANSMYOCARDIAL REVASCULARIZATION

NASAL AIRWAY EVALUATION Acoustic Reflex Technology Acoustic Rhinometry Optical Rhinometry Rhinomanometry Sleep Sonography

BLINCYTO (blinatumomab)

GATTEX (teduglutide [rdna origin])

PERCUTANEOUS TIBIAL NERVE STIMULATION

MYLOTARG (gemtuzumab ozogamicin)

RELISTOR (methylnaltrexone bromide) INJECTION FOR SUBCUTANEOUS USE

TYMLOS (abaloparatide)

TREATMENTS FOR GAUCHER DISEASE

CIMZIA (certolizumab pegol)

APOKYN (apomorphine hydrochloride)

GENETIC TESTING FOR FLT3, NPM1 AND CEBPA VARIANTS IN CYTOGENETICALLY NORMAL ACUTE MYELOID LEUKEMIA

Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document.

AUTOLOGOUS CHONDROCYTE IMPLANTATION FOR FOCAL ARTICULAR CARTILAGE LESIONS

PERCUTANEOUS TIBIAL NERVE STIMULATION

SOMATULINE DEPOT (lanreotide acetate)

ELECTROMYOGRAPHY (EMG) AND NERVE CONDUCTION STUDIES (NCS)

LIMB COMPRESSION DEVICES FOR VENOUS THROMBOEMBOLISM PROPHYLAXIS

BIVENTRICULAR PACEMAKER (CARDIAC RESYNCHRONIZATION THERAPY) FOR THE TREATMENT OF HEART FAILURE

H.P. ACTHAR GEL (repository corticotropin injection)

GENETIC TESTING FOR HEREDITARY BREAST AND OVARIAN CANCER SYNDROME BRCA1 BRCA2

PARSABIV (etelcalcetide)

Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document.

Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document.

INJECTABLE BULKING AGENTS FOR THE TREATMENT OF URINARY AND FECAL INCONTINENCE

BONIVA (ibandronate sodium)

ALPHA-FETOPROTEIN-L3 FOR DETECTION OF HEPATOCELLULAR CANCER

Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document.

HEMATOPOIETIC CELL TRANSPLANTATION FOR HODGKIN LYMPHOMA

BRINEURA (cerliponase alfa)

ELECTRIC TUMOR TREATMENT FIELDS

VYXEOS (daunorubicin and cytarabine)

GENETIC TESTING FOR TARGETED THERAPY FOR NON-SMALL CELL LUNG CANCER (NSCLC)

BREAST RECONSTRUCTION/REMOVAL AND REPLACEMENT OF IMPLANTS

PERCUTANEOUS TRANSCATHETER CLOSURE OF PARAVALVULAR LEAK

TYSABRI FOR CROHN S DISEASE

HEMATOPOIETIC CELL TRANSPLANTATION FOR SOLID TUMORS OF CHILDHOOD

MEDICAL COVERAGE GUIDELINES ORIGINAL EFFECTIVE DATE: 12/19/17 SECTION: MEDICINE LAST REVIEW DATE: LAST CRITERIA REVISION DATE: ARCHIVE DATE:

MEDICAL COVERAGE GUIDELINES ORIGINAL EFFECTIVE DATE: 11/14/17 SECTION: DRUGS LAST REVIEW DATE: LAST CRITERIA REVISION DATE: ARCHIVE DATE:

HEMATOPOIETIC CELL TRANSPLANTATION FOR CHRONIC MYELOID LEUKEMIA

INTRAOPERATIVE RADIATION THERAPY

VESTIBULAR FUNCTION TESTING

KYMRIAH (tisagenlecleucel)

LUXTURNA (voretigene neparovec-rzyl)

DECISIONDx BIOMARKER TESTS

MEASUREMENT OF EXHALED NITRIC OXIDE AND EXHALED BREATH CONDENSATE

MEDICAL COVERAGE GUIDELINES ORIGINAL EFFECTIVE DATE: 03/07/18 SECTION: DRUGS LAST REVIEW DATE: 02/19/19 LAST CRITERIA REVISION DATE: ARCHIVE DATE:

ACTEMRA (tocilizumab)

STRENSIQ (asfotase alfa)

RADIOFREQUENCY ABLATION OR CRYOABLATION FOR ESOPHAGEAL DISORDERS

COSENTYX (secukinumab)

Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document.

YESCARTA (axicabtagene ciloleucel)

Medical Policy. MP Dynamic Spinal Visualization

NONINVASIVE TECHNIQUES FOR EVALUATION AND MONITORING OF CHRONIC LIVER DISEASE

Dynamic Spinal Visualization and Vertebral Motion Analysis

Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document.

Transcription:

DYNAMIC SPINAL VISUALIZATION Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Medical Coverage Guideline must be read in its entirety to determine coverage eligibility, if any. This Medical Coverage Guideline provides information related to coverage determinations only and does not imply that a service or treatment is clinically appropriate or inappropriate. The provider and the member are responsible for all decisions regarding the appropriateness of care. Providers should provide BCBSAZ complete medical rationale when requesting any exceptions to these guidelines. The section identified as Description defines or describes a service, procedure, medical device or drug and is in no way intended as a statement of medical necessity and/or coverage. The section identified as Criteria defines criteria to determine whether a service, procedure, medical device or drug is considered medically necessary or experimental or investigational. State or federal mandates, e.g., FEP program, may dictate that any drug, device or biological product approved by the U.S. Food and Drug Administration (FDA) may not be considered experimental or investigational and thus the drug, device or biological product may be assessed only on the basis of medical necessity. Medical Coverage Guidelines are subject to change as new information becomes available. For purposes of this Medical Coverage Guideline, the terms "experimental" and "investigational" are considered to be interchangeable. BLUE CROSS, BLUE SHIELD and the Cross and Shield Symbols are registered service marks of the Blue Cross and Blue Shield Association, an association of independent Blue Cross and Blue Shield Plans. All other trademarks and service marks contained in this guideline are the property of their respective owners, which are not affiliated with BCBSAZ. Description: Dynamic spinal visualization is an imaging method to allow simultaneous visualization of internal body structures (vertebrae) and external body movement. Dynamic spinal visualization has been investigated for the evaluation of spinal disorders and encompasses the following technologies: digital motion imaging, digital motion X-ray (DMX), digital motion fluoroscopy and videofluoroscopy. Dynamic magnetic resonance imaging (MRI) has also been investigated for spinal imaging. O476.15.docx Page 1 of 5

Criteria: Dynamic spinal visualization is considered experimental or investigational based upon: 1. Insufficient scientific evidence to permit conclusions concerning the effect on health outcomes, and 2. Insufficient evidence to support improvement of the net health outcome, and 3. Insufficient evidence to support improvement of the net health outcome as much as, or more than, established alternatives, and 4. Insufficient evidence to support improvement outside the investigational setting. Resources: Literature reviewed 04/25/17. We do not include marketing materials, poster boards and nonpublished literature in our review. The BCBS Association Medical Policy Reference Manual (MPRM) policy is included in our guideline review. References cited in the MPRM policy are not duplicated on this guideline. 1. 6.01.46 BCBS Association Medical Policy Reference Manual. Dynamic Spinal Visualization. Re-issue date 03/09/2017, issue date 12/12/2006. 2. American Chiropractic College of Radiology. Protocol for the Use of Spinal Videofluoroscopy. Accessed 09/15/2004. 3. Council on Diagnostic Imaging of the American Chiropractic Association Inc. Position Statements. 06/13/1991. 4. Fujiwara A, Tamai K, An HS, et al. The relationship between disc degeneration, facet joint osteoarthritis, and stability of the degenerative lumbar spine. J Spinal Disord. 2000 Oct 2000;13(5):444-450. 5. Hino H, Abumi K, Kanayama M, Kaneda K. Dynamic motion analysis of normal and unstable cervical spines using cineradiography. An in vivo study. Spine. 1999 Jan 15 1999;24(2):163-168. 6. Mercy Guidelines. Videofluoroscopy-Position Statement. Accessed 09/15/2004. 7. Okawa A, Shinomiya K, Komori H, Muneta T, Arai Y, Nakai O. Dynamic motion study of the whole lumbar spine by videofluoroscopy. Spine. 1998 Aug 15 1998;23(16):1743-1749. 8. Ono K, Kaneoka K, Hattori S, et al. Cervical vertebral motions and biomechanical responses to direct loading of human head. Traffic Inj Prev. 2003 Jun 2003;4(2):141-152. O476.15.docx Page 2 of 5

Resources: (cont.) 9. Takayanagi K, Takahashi K, Yamagata M, Moriya H, Kitahara H, Tamaki T. Using cineradiography for continuous dynamic-motion analysis of the lumbar spine. Spine. 2001 Sep 1 2001;26(17):1858-1865. 10. Teyhen DS, Flynn TW, Bovik AC, Abraham LD. A new technique for digital fluoroscopic video assessment of sagittal plane lumbar spine motion. Spine. 2005 Jul 15 2005;30(14):E406-413. 11. Wong KW, Leong JC, Chan MK, Luk KD, Lu WW. The flexion-extension profile of lumbar spine in 100 healthy volunteers. Spine. 2004 Aug 1 2004;29(15):1636-1641. 12. Wong KW, Luk KD, Leong JC, Wong SF, Wong KK. Continuous dynamic spinal motion analysis. Spine. 2006 Feb 15 2006;31(4):414-419. 13. Wu SK, Lan HH, Kuo LC, Tsai SW, Chen CL, Su FC. The feasibility of a video-based motion analysis system in measuring the segmental movements between upper and lower cervical spine. Gait Posture. 2006 Sep 18 2006. O476.15.docx Page 3 of 5

Non-Discrimination Statement: Blue Cross Blue Shield of Arizona (BCBSAZ) complies with applicable Federal civil rights laws and does not discriminate on the basis of race, color, national origin, age, disability or sex. BCBSAZ provides appropriate free aids and services, such as qualified interpreters and written information in other formats, to people with disabilities to communicate effectively with us. BCBSAZ also provides free language services to people whose primary language is not English, such as qualified interpreters and information written in other languages. If you need these services, call (602) 864-4884 for Spanish and (877) 475-4799 for all other languages and other aids and services. If you believe that BCBSAZ has failed to provide these services or discriminated in another way on the basis of race, color, national origin, age, disability or sex, you can file a grievance with: BCBSAZ s Civil Rights Coordinator, Attn: Civil Rights Coordinator, Blue Cross Blue Shield of Arizona, P.O. Box 13466, Phoenix, AZ 85002-3466, (602) 864-2288, TTY/TDD (602) 864-4823, crc@azblue.com. You can file a grievance in person or by mail or email. If you need help filing a grievance BCBSAZ s Civil Rights Coordinator is available to help you. You can also file a civil rights complaint with the U.S. Department of Health and Human Services, Office for Civil Rights electronically through the Office for Civil Rights Complaint Portal, available at https://ocrportal.hhs.gov/ocr/portal/lobby.jsf, or by mail or phone at: U.S. Department of Health and Human Services, 200 Independence Avenue SW., Room 509F, HHH Building, Washington, DC 20201, 1 800 368 1019, 800 537 7697 (TDD). Complaint forms are available at http://www.hhs.gov/ocr/office/file/index.html Multi-Language Interpreter Services: O476.15.docx Page 4 of 5

Multi-Language Interpreter Services: (cont.) O476.15.docx Page 5 of 5